The safety of therapeutic monoclonal antibodies: implications for cancer therapy including immuno-checkpoint inhibitors

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00209805%3A_____%2F16%3AN0000059" target="_blank" >RIV/00209805:_____/16:N0000059 - isvavai.cz</a>

Alternative codes found

RIV/00216224:14110/16:00093104

Result on the web

<a href="http://www.biomed.cas.cz/physiolres/pdf/65/65_S455.pdf" target="_blank" >http://www.biomed.cas.cz/physiolres/pdf/65/65_S455.pdf</a>

DOI - Digital Object Identifier

—

Result language

angličtina

Original language name

The safety of therapeutic monoclonal antibodies: implications for cancer therapy including immuno-checkpoint inhibitors

Original language description

Monoclonal antibody-based treatment of cancer has been established as one of the most successful therapeutic strategies for both hematologic malignancies and solid tumors. In addition to targeting cancer antigens antibodies can also modulace immunological pathways that are critical to immune surveillance. Antibody therapy directed against several negative immunologic regulators (checkpoints) is demonstrating significant success in the past few years. Immune checkpoint inhibitors, ipilimumab, pembrolizumab and nivolumab, have shown significant clinical benefit in several malignancies and are already approved for advanced melanoma and squamous NSCLC. Based on thein mechanism of action, these agents can exert toxicities that are unlike conventional cytotoxic chemotherapy, whose nature is close to autoimmune diseases - immune related adverse events (irAEs). In this review we focus on the spectrum of irAEs associated with immune checkpoint antibodies, discussing the pharmacological treatment strategy and possible clinical impact.

Czech name

—

Czech description

—

Type

J_x - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)

CEP classification

FD - Oncology and haematology

OECD FORD branch

—

Project

<a href="/en/project/LM2015090" target="_blank" >LM2015090: Czech National Node to the European Clinical Research Infrastructure Network</a><br>

Continuities

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Publication year

2016

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

Physiological Research

ISSN

0862-8408

e-ISSN

—

Volume of the periodical

65

Issue of the periodical within the volume

Suppl4

Country of publishing house

CZ - CZECH REPUBLIC

Number of pages

8

Pages from-to

S455-S462

UT code for WoS article

000392029200005

EID of the result in the Scopus database

—